金水宝片对自体造血干细胞移植术后患者造血及免疫功能重建作用的临床研究
2025-08-09张伟明钟幸余娜莎宋相祥黄燕
Clinical Study on the Effect of Jinshuibao Tablets on Hematopoieticand Immune Function Reconstruction in Patients after Autologous Hematopoietic Stem Cell Transplantation/ZHANG Weiming, ZHONG Xing, YU Nasha,SONG Xiangxiang,HUANG Yan.//Medical Innovation of China,2025,22(18): 019-023
[Abstract]Objective:To analyze the effect of Jinshuibao Tablets on hematopoietic and immune function reconstruction in patients undergoing autologous hematopoietic stem cel transplantation.Method: Sixty patients who underwent autologous hematopoietic stem celltransplantation in Jiangxi Cancer Hospital from January 2021 to October 2O22 were selected and randomly divided into two groups according to a 1:1 ratio, with 30 patients in each group.The control group received conventional treatment, while theexperimental group received conventional treatment + Jinshuibao Tablets.The levels of blood routine,immunoglobulin,and Tlymphocyte subsets between two groups of patients werecompared,and thereconstruction time of autologous hematopoietic stemcellsand toxic side effcts between the two groups of patients were compared.Result: Before transplantation,there were no significant changes in various indicators between the two groups ( P gt;0.05).After 30 d of transplantation, the hemoglobin, platelet count,and white bloodcell levels in the experimental group were higher than those in the control group, the differences were statistically significant ( P lt;0.05).After 3O d of transplantation,the immune protein indicators such as IgG,IgA,IgMin the experimental group were higher than those in the control group,andtheTlymphocyte subpopulation indicators such as CD 3+ ,CD 4+ and CD4+/CD8 + were all higher than those in the control group, the differences were statistically significant ( P lt;0.05). The reconstruction time of autologous hematopoietic stem cells in the experimental group was shorter than that inthe control group,thedifferences were statisticalysignificant( P lt;0.05). Thetotal incidence of toxicside effcts of the experimental groupwas significantlylower thanthatof the control group,the difference was statistically significant ( P lt;0.05). Conclusion: The application of Jinshuibao Tablets in patients undergoing autologous hematopoietic stemcell transplantation can help maintain the stabilityof their blood routine,improve theirlevels ofimmune proteins andTlymphocyte subsets,and accelerate the reconstruction of their immune function,it has high practicality and safety.
[Key words]Jinshuibao TabletsAutologous hematopoietic stem celltransplantationImmune function
Toxicity First-author'saddress:Department of Lymphatic and Hematological Oncology,Jiangxi Cancer
Hospital, Nanchang 33o029, China doi:10.3969/j.issn.1674-4985.2025.18.005
自体造血干细胞移植(autologoushematopoieticstemcelltransplantation,ASCT)主要是通过将患者自身的造血干细胞进行收集并储藏,患者经过高剂量的化疗或放疗后,再将其收集到的十细胞移植到患者体内的一种治疗手段,这种方式可以帮助患者恢复其造血系统及免疫功能[]。然而,移植术后患者的造血及免疫功能需要进行重建,这个过程复杂且关键,可对患者预后的康复以及生存质量造成直接影响,因此,需要寻求更加有效的治疗方案以促进其ASCT术后患者造血及免疫功能的恢复[2。金水宝片是临床常用的一种中药制剂,具有调节免疫、保护肾脏、改善肺功能等多种效果[3-4]。近年来,越来越多的研究关注到金水宝片在造血及免疫功能调节方面有着潜在的应用价值[5]。鉴于此,本研究将通过对患者的临床指标进行监测和分析,并评估金水宝片在促进自体造血干细胞植入、加速免疫功能恢复等方面的疗效和安全性。期望通过本次研究能够为ASCT术后患者的康复提供新的治疗思路和指导,现报道如下。
1资料与方法
1.1一般资料
选取2021年1月—2022年10月江西省肿瘤医院收治的60例自体造血干细胞移植患者作为研究对象。(1)纳入标准: ① 经病理结果确诊为恶性淋巴瘤,且年龄 gt;18 岁; ② 化疗后疗效评估为完全缓解,且干细胞采集数量达标(单个核细胞 gt;2×108/kg CD34细胞 gt;2×106/kg ); ③ KPS评分 gt;80 分; ④ 预计生存期 gt;3 个月,且无主要器官功能损害。(2)排除标准: ① 合并严重精神疾病或无法正常沟通;② 患者处于哺乳期或妊娠期; ③ 对研究药物存在禁忌证; ④ 患者依从性差或中途退出。……
